Ovarian Cancer PDX Models

With over 60 Ovarian cancer PDX models available for studies Champion’s Oncology has an extensive and diverse cohort for oncology drug development.

A unique set of over 40 models have been established from patients treated with platinum therapies (and subsequently benchmarked for in vivo response to these agents).

Together with next generation sequencing data (WES and RNASeq) on over 55 of these PDXs, studies run with these models can potentially identify therapies to overcome resistance to standard of care agents as well as biomarkers of response/non-response.

Patient Demographics

Clinical Stage:
- IV: 40%
- III: 50%
- II: 8%
- I: 3%

Treatment History:
- Pretreated: 81%
- Naive: 19%

Ovarian Platinum Pretreatment Status:
- Naive: 26%
- Sensitive: 47%
- Refractory: 17%
- Resistant: 8%

Lines of Therapy:
- Carboplatin/Paclitaxel: 20%
- Olaparib: 43%

Standards of Care

Model responses to standards of care have been documented and can be compared to the response of oncology agents in development.
Molecular Analysis

Sequencing of Champions’ Ovarian PDX cohort has identified important mutations in BRCA1/2 and other Homologous Recombination Deficient (HRD) pathway genes.


VUS = variant of unknown significance

PARPi Responses

Ovarian models with BRCA1/2 and BRCA-like mutations have been screened for response to the PARP inhibitor Olaparib. These responses can be correlated with platinum responses and clinical trial outcomes.

BRCA wild type (CTG-1305 n=1-3)

BRCA1 mutated (CTG-1789 n=1)

Please visit championsoncology.com for access to the Champions TumorGraft database and updated information about Champions Oncology PDX models.